21. THE MERCK MANUAL, Sec. 11, Ch. 132, Thrombotic Disorders hyperhomocysteinemia. Plasma homocysteine levels are elevated tenfold or greater hyperhomocysteinemia is also strongly correlated with atherosclerotic http://www.merck.com/mrkshared/mmanual/section11/chapter132/132a.jsp

22. Entrez PubMed Furthermore, we investigated the combined effect of hyperhomocysteinemia The prevalence of fasting hyperhomocysteinemia ( 14.0 micromol/L) was 25.8%. http://www.nutritionandmetabolism.com/pubmed/9445267

My NCBI [Sign In] [Register] All Databases ... Books Search PubMed Protein Nucleotide Structure Genome Books CancerChromosomes Conserved Domains 3D Domains Gene Genome Project GENSAT GEO Profiles GEO DataSets HomoloGene Journals MeSH NCBI Web Site NLM Catalog OMIA OMIM PMC PopSet Probe PubChem BioAssay PubChem Compound PubChem Substance SNP Taxonomy UniGene UniSTS for Limits Preview/Index History Clipboard Details About Entrez Text Version Entrez PubMed Overview FAQ Tutorial New/Noteworthy ... E-Utilities PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher ... Cubby Related Resources Order Documents NLM Mobile NLM Catalog NLM Gateway ... PubMed Central Display Summary Brief Abstract Citation MEDLINE XML UI List LinkOut ASN.1 Related Articles Cited Articles Cited in Books CancerChrom Links Domain Links 3D Domain Links GEO DataSet Links Gene Links Gene (GeneRIF) Links Genome Links Project Links GENSAT Links GEO Profile Links HomoloGene Links Nucleotide Links OMIA Links OMIM Links BioAssay Links Compound Links Compound via MeSH Substance Links Substance via MeSH PMC Links Cited in PMC PopSet Links Probe Links Protein Links SNP Links Structure Links UniGene Links UniSTS Links Show Sort by Author Journal Pub Date Send to Text File Clipboard E-mail Order All: 1 Review: Arterioscler Thromb Vasc Biol.

23. Entrez PubMed hyperhomocysteinemia and the endocrine system implications for atherosclerosis and thrombosis. Fonseca V, Guba SC, Fink LM. http://www.nutritionandmetabolism.com/pubmed/10529901

My NCBI [Sign In] [Register] All Databases ... Books Search PubMed Protein Nucleotide Structure Genome Books CancerChromosomes Conserved Domains 3D Domains Gene Genome Project GENSAT GEO Profiles GEO DataSets HomoloGene Journals MeSH NCBI Web Site NLM Catalog OMIA OMIM PMC PopSet Probe PubChem BioAssay PubChem Compound PubChem Substance SNP Taxonomy UniGene UniSTS for Limits Preview/Index History Clipboard Details About Entrez Text Version Entrez PubMed Overview FAQ Tutorial New/Noteworthy ... E-Utilities PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher ... Cubby Related Resources Order Documents NLM Mobile NLM Catalog NLM Gateway ... PubMed Central Display Summary Brief Abstract Citation MEDLINE XML UI List LinkOut ASN.1 Related Articles Cited Articles Cited in Books CancerChrom Links Domain Links 3D Domain Links GEO DataSet Links Gene Links Gene (GeneRIF) Links Genome Links Project Links GENSAT Links GEO Profile Links HomoloGene Links Nucleotide Links OMIA Links OMIM Links BioAssay Links Compound Links Compound via MeSH Substance Links Substance via MeSH PMC Links Cited in PMC PopSet Links Probe Links Protein Links SNP Links Structure Links UniGene Links UniSTS Links Show Sort by Author Journal Pub Date Send to Text File Clipboard E-mail Order All: 1 Review: 1 Endocr Rev.

24. Entrez PubMed hyperhomocysteinemia, atherosclerosis and thrombosis. Cattaneo M. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine, http://genomebiology.com/pubmed/10063987

My NCBI [Sign In] [Register] All Databases ... Books Search PubMed Protein Nucleotide Structure Genome Books CancerChromosomes Conserved Domains 3D Domains Gene Genome Project GENSAT GEO Profiles GEO DataSets HomoloGene Journals MeSH NCBI Web Site NLM Catalog OMIA OMIM PMC PopSet Probe PubChem BioAssay PubChem Compound PubChem Substance SNP Taxonomy UniGene UniSTS for Limits Preview/Index History Clipboard Details About Entrez Text Version Entrez PubMed Overview FAQ Tutorial New/Noteworthy ... E-Utilities PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher ... Cubby Related Resources Order Documents NLM Mobile NLM Catalog NLM Gateway ... PubMed Central Display Summary Brief Abstract Citation MEDLINE XML UI List LinkOut ASN.1 Related Articles Cited Articles Cited in Books CancerChrom Links Domain Links 3D Domain Links GEO DataSet Links Gene Links Gene (GeneRIF) Links Genome Links Project Links GENSAT Links GEO Profile Links HomoloGene Links Nucleotide Links OMIA Links OMIM Links BioAssay Links Compound Links Compound via MeSH Substance Links Substance via MeSH PMC Links Cited in PMC PopSet Links Probe Links Protein Links SNP Links Structure Links UniGene Links UniSTS Links Show Sort by Author Journal Pub Date Send to Text File Clipboard E-mail Order All: 1 Review: 1 Thromb Haemost.

25. Homocysteine had hyperhomocysteinemia were daily given 100 mcg B12 for three months B-12 supplementation is effective in alleviating hyperhomocysteinemia - 100 http://qualitycounts.com/fphomocysteine.html

26. Project: Genetic Causes Of Hyperhomocysteinemia (mHH) (www.onderzoekinformatie.n Project Genetic causes of hyperhomocysteinemia (mHH). Show printerfriendly view Print View switch to nl mutation. Titel, Genetische oorzaken van http://www.onderzoekinformatie.nl/en/oi/nod/onderzoek/OND1270367/toon

Login English KNAW Research Information NOD - Dutch Research Database ... Research entire www.onderzoekinformatie.nl site fuzzy match Project: Genetic causes of hyperhomocysteinemia (mHH) Print View Titel Genetische oorzaken van hyperhomocyste¯nemie (mHH) Period 01/1997 - unknown Related organisations Secretariat: Department of Paediatrics (KUN) Related persons Project leader: Dr. H.J. Blom Project leader: Dr. G.H.J. Boers Classification public health and health care biochemistry genetics internal medicine ... NOD page Last modified: 17-01-2002 00:00

27. Project: Molecular Genetic Basis Of Hyperhomocysteinemia. (www.onderzoekinformat Abstract, Part 1 Which mutations are causing mild hyperhomocysteinemia? Mild hyperhomocysteinemia is a risk factor for arterial as well as venous http://www.onderzoekinformatie.nl/en/oi/nod/onderzoek/OND1271280/toon

Login English KNAW Research Information NOD - Dutch Research Database ... Research entire www.onderzoekinformatie.nl site fuzzy match Project: Molecular genetic basis of hyperhomocysteinemia. Print View Titel Moleculair genetisch onderzoek van hyperhomocyste¯nemie. Abstract Part 1: Which mutations are causing mild hyperhomocysteinemia? Mild hyperhomocysteinemia is a risk factor for arterial as well as venous occlusions. Both genetic and acquired factors are known to influence the plasma homocysteine concentration. Different family studies reveal that the plasma homocysteine concentration is strongly influenced by genetic components. Until now we have discovered two mutations in the methylene tetrahydrofolate reductase gene which are genetic causes of mild hyperhomocysteinemia. The folate status is strongly influencing this phenotype/genotype relation (nature/nurture). These mutations can only explain a very small part of the genetic component of mild hyperhomocysteinemia. By use of different molecular genetic techniques genes involved in homocysteine metabolism will be investigated for homocysteine increasing mutations. Period Related organisations Secretariat: Department of Paediatrics (KUN) Related persons Project leader: Dr. H.J. Blom

28. HUM-MOLGEN Events: 4th Conference On Hyperhomocysteinemia central resource for events in human genetics and molecular biology. http://hum-molgen.org/meetings/meetings/2447.html

home genetic news bioinformatics biotechnology ... 4th Conference on Hyperhomocysteinemia July 19, 2004 Medical Research (others) Dep. Clinical Chemistry, Saarland University Hospitals, Congress Hall Saarbruecken/Germany 14th-16th April 2005 Thursday, 14.04.2005 Session 1: Epidemiology and Clinical Studies (Part 1) D.S. Wald - Homocysteine and risk of cardiovascular disease and stroke (UK) L.D. Botto - Improvement in stroke mortality, United States 1990-2001, and its relation to folic acid fortification and other factors (USA) R. Green - In the post-folic acid fortification era cobalamin deficiency has become the most common modifiable cause of hyperhomocysteinemia: Evidence from a population-based study using holoTC ll and plasma MMA measurements (USA) W. Herrmann - Response of homocysteine and methionine cycle intermediates to vitamin treatment in dialysis patients (D) R.S. Vasan - Plasma homocysteine and risk for congestive heart failure (USA) Session 2: Epidemiology and Clinical Studies (Part 2) C.D. Stehouwer - Hyperhomocysteinemia in diabetes - a double hit? (NL) O.M. Hess - Effect of homocysteine-lowering therapy on restenosis (CH)

29. Clinical Trial: Randomized Study Of Folic Acid Therapy For Hyperhomocysteinemia Randomized Study of Folic Acid Therapy for hyperhomocysteinemia in Patients with End Stage hyperhomocysteinemia, Drug cyanocobalamin Drug folic acid http://www.clinicaltrials.gov/ct/show/NCT00004495

Home Search Browse Resources ... About Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients with End Stage Renal Disease Receiving Hemodialysis This study is currently recruiting patients. Verified by FDA Office of Orphan Products Development August 1999 Sponsors and Collaborators: FDA Office of Orphan Products Development Georgetown University Information provided by: FDA Office of Orphan Products Development ClinicalTrials.gov Identifier: Purpose OBJECTIVES: I. Compare the efficacy of two doses of folic acid in normalizing plasma total homocysteine concentration in patients with end stage renal disease receiving regular hemodialysis therapy resulting in hyperhomocysteinemia. II. Determine the requirement of co-supplementation with extra pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) daily in these patients. III. Assess the safety and tolerability of this therapy in these patients. Condition Intervention End Stage Renal Disease Hyperhomocysteinemia Drug: cyanocobalamin Drug: folic acid Drug: pyridoxine MedlinePlus related topics: Genetic Disorders Kidney Failure Metabolic Disorders Study Type: Interventional Study Design: Treatment, Efficacy Study

30. Hyperhomocysteinemia hyperhomocysteinemia. Printable version. Etiology. methionine synthase deficiency by mutations of gene MTR (1p43). Mutations in the MTR gene result in the http://www.humpath.com/article.php3?id_article=1714

31. PharmGKB: Hyperhomocysteinemia hyperhomocysteinemia Submitted by Alexander Steven Whitehead involving CBS, MTHFR, MTR, MTRR, NOS3, TYMS, and hyperhomocysteinemia. http://www.pharmgkb.org/do/serve?objId=PA446892&objCls=Disease

32. NEJM -- Hyperhomocysteinemia As A Risk Factor For Deep-Vein Thrombosis Original Article from The New England Journal of Medicine hyperhomocysteinemia as a Risk Factor for DeepVein Thrombosis. http://content.nejm.org/cgi/content/short/334/12/759

HOME SEARCH CURRENT ISSUE PAST ISSUES ... HELP Please sign in for full text and personal services Previous Volume 334:759-762 March 21, 1996 Number 12 Next Hyperhomocysteinemia as a Risk Factor for Deep-Vein Thrombosis Full Text PDF Letters Add to Personal Archive ... PubMed Citation ABSTRACT Background Previous studies have suggested that hyperhomocysteinemia may be a risk factor for venous thrombosis. To assess the risk of venous thrombosis associated with hyperhomocysteinemia, we studied plasma homocysteine levels in patients with a first episode of deep-vein thrombosis and in normal control subjects. Methods We measured plasma homocysteine levels in 269 patients with a first, objectively diagnosed episode of deep-vein thrombosis and in 269 healthy controls matched to the patients according to age and sex. Hyperhomocysteinemia was defined as a plasma homocysteine level above the 95th percentile in the control Results Of the 269 patients, 28 (10 percent) had plasma homocysteine levels above the 95th percentile for the controls, as compared with 13 of the controls (matched odds ratio, 2.5; 95 percent

33. NEJM -- Hyperhomocysteinemia As A Risk Factor For Deep-Vein Thrombosis Correspondence from The New England Journal of Medicine hyperhomocysteinemia as a Risk Factor for DeepVein Thrombosis. http://content.nejm.org/cgi/content/short/335/13/974

HOME SEARCH CURRENT ISSUE PAST ISSUES ... HELP Please sign in for full text and personal services Previous Volume 335:974-976 September 26, 1996 Number 13 Next A correction has been published: N Engl J Med 1997;336(19):1400 Hyperhomocysteinemia as a Risk Factor for Deep-Vein Thrombosis Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings. Full Text Add to Personal Archive Add to Citation Manager E-mail When Cited ... PubMed Citation To the Editor: The article by den Heijer et al. (March 21 issue) supports our finding that hyperhomocysteinemia is a risk factor for deep-vein thrombosis that is independent of coexisting abnormalities of naturally occurring anticoagulants. This important confirmation challenges the suggestion by Mandel et al., in their article in the same issue, that hyperhomocysteinemia increases the risk of thrombosis only if the elevation in homocysteinemia is associated with the presence of factor V Leiden. Unlike our study of patients with early-onset deep-vein thrombosis and their previous study of patients with recurrent deep-vein thrombosis

34. Hyperhomocysteinemia hyperhomocysteinemia Medical.WebEnds.com. hyperhomocysteinemia. hyperhomocysteinemias. An inborn error of methionone metabolism which produces an excess http://medical.webends.com/kw/Hyperhomocysteinemia

Medical.WebEnds.com - Medical Terminology Dictionary A B C D ... Z WWW Medical.WebEnds.com Hyperhomocysteinemia Hyperhomocysteinemias An inborn error of methionone metabolism which produces an excess of homocysteine in the blood. It is often caused by a deficiency of CYSTATHIONINE BETA-SYNTHASE and is a risk factor for coronary vascular disease Google links Processing time was 0.065723180770874 seconds.

35. Log In Problems What is the relationship between both elevated hyperhomocysteinemia and low vitamin B6 levels and the presence of nonvalvular AF? http://www.medscape.com/viewarticle/490217

Unable to Deliver Requested Page In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site. To find out how to adjust your browser settings to accept cookies, please click here Medscape uses cookies to customize the site based on the information we collect at registration. The cookies contain no personally identifiable information and have no effect once you leave the Medscape site. You can read more about our use of cookies in our About Medscape Help WebMD Health

36. Alternative Medicine Review: Coronary Endothelial Function In Hyperhomocysteinem Coronary endothelial function in hyperhomocysteinemia improvement after BACKGROUND hyperhomocysteinemia is an independent risk factor for CAD. http://www.findarticles.com/p/articles/mi_m0FDN/is_6_7/ai_96416626

@import url(/css/us/style1.css); @import url(/css/us/searchResult1.css); @import url(/css/us/articles.css); @import url(/css/us/artHome1.css); Advanced Search Home Help IN free articles only all articles this publication Automotive Sports 10,000,000 articles - not found on any other search engine. FindArticles Alternative Medicine Review Dec 2002 Content provided in partnership with 10,000,000 articles Not found on any other search engine. Related Searches Homocysteine / Measurement Coronary heart disease / Risk factors Vitamin B12 / Administration and dosage Vitamin B12 / Physiological aspects ... Folic acid / Administration and dosage Featured Titles for AAACN Viewpoint ABNF Journal, The AIDS Treatment News AMAA Journal ... View all titles in this topic Hot New Articles by Topic Automotive Sports Top Articles Ever by Topic Automotive Sports Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease Alternative Medicine Review Dec, 2002 by FF Willems WR Aengevaeren GH Boers Save a personal copy of this article and quickly find it again with Furl.net. It's free!

37. Alternative Medicine Review: Hyperhomocysteinemia In Children Treated With Sodiu Full text of the article, hyperhomocysteinemia in children treated with sodium valproate and carbamazepine Abstract from Alternative Medicine Review, http://www.findarticles.com/p/articles/mi_m0FDN/is_6_5/ai_68727276

@import url(/css/us/style1.css); @import url(/css/us/searchResult1.css); @import url(/css/us/articles.css); @import url(/css/us/artHome1.css); Advanced Search Home Help IN free articles only all articles this publication Automotive Sports 10,000,000 articles - not found on any other search engine. FindArticles Alternative Medicine Review Dec 2000 Content provided in partnership with 10,000,000 articles Not found on any other search engine. Related Searches Carbamazepine / Adverse and side effects Valproic acid / Adverse and side effects Homocysteine / Effect of drugs on Featured Titles for AAACN Viewpoint ABNF Journal, The AIDS Treatment News AMAA Journal ... View all titles in this topic Hot New Articles by Topic Automotive Sports Top Articles Ever by Topic Automotive Sports Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine - Abstract Alternative Medicine Review Dec, 2000 by Verrotti A Pascarella R Trotta D Save a personal copy of this article and quickly find it again with Furl.net. It's free! Save it.

38. Role Of Hyperhomocysteinemia In Endothelial Dysfunction And Atherothrombotic Dis Cell death and differentiation is a monthly research journal focused on the exciting field of programmed cell death and apoptosis. http://www.nature.com/doifinder/10.1038/sj.cdd.4401451

NATURE.COM NEWS@NATURE.COM NATUREJOBS NATUREEVENTS ... Help SEARCH my account e-alerts subscribe register ... Site features NPG Subject areas Access material from all our publications in your subject area: Biotechnology Cancer Chemistry NEW! Dentistry Development Drug Discovery Earth Sciences ... Physics July 2004, Volume 11, Supplement 1, Pages S56-S64 Table of contents Previous Next Full text ... PDF Review Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease R C Austin , S R Lentz and G H Werstuck Department of Pathology and Molecular Medicine, McMaster University and the Henderson Research Centre, Hamilton, Ontario, Canada Veterans Affairs Medical Center and Department of Internal Medicine, University of Iowa, Iowa City, IA, USA Departments of Biochemistry and Medicine, McMaster University, Hamilton, Ontario, Canada Correspondence to: RC Austin, Henderson Research Centre, 711 Concession Street, Hamilton, Ontario, Canada L8V 1C3. Tel: +1 905 527 2299 ext. 42628; Fax: +1 905 575 2646; E-mail: raustin@thrombosis.hhscr.org Edited by G Melino Abstract Hyperhomocysteinemia (HHcy) is an independent risk factor for cardiovascular disease, including ischemic heart disease, stroke, and peripheral vascular disease. Mutations in the enzymes responsible for homocysteine metabolism, particularly cystathionine

39. Hyperhomocysteinemia - Chapter 3: Hypercoagulable States In Venous Disease Elevated homocysteine levels (hyperhomocysteinemia) have been found to increase the risk of venous thrombosis up to fourfold. According to one multicenter http://www.venous-info.com/handbook/hbk03g.html

Homocysteine is an amino acid derived from methionine (an essential amino acid). Amino acids are the building blocks of proteins. Elevated homocysteine levels (hyperhomocysteinemia) have been found to increase the risk of venous thrombosis up to fourfold. According to one multicenter study, high blood levels of homocysteine are associated with early onset of vascular disease and venous thrombosis (10–25%) and with recurrence (19%) of deep venous thrombosis after 2 years. High homocysteine levels in people who have no symptoms can be normalized with supplements of folic acid, vitamin B , and vitamin B (although the benefit is not proved). Patients who have had deep venous thrombosis should have anticoagulation therapy with warfarin or low molecular weight heparin. The physician determines the duration of this treatment. Lifelong anticoagulation may be considered for patients with a high risk for recurrent deep venous thrombosis.

40. Hyperhomocysteinemia Presenting As Superior Mesenteric Artery Thrombosis Alexand Indian J Gastroenterol, The official publication of the Indian Society of Gastroenterology (ISG) http://www.indianjgastro.com/article.asp?issn=0254-8860;year=2005;volume=24;issu

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 2     21-40 of 95    Back | 1  | 2  | 3  | 4  | 5  | Next 20